{"retracted":false,"update":{"timestamp":1480550400000,"doi":"10.1038/srep38270","type":"correction"},"doi":"10.1038/srep36371","journal":"Scientific Reports","publisher":"Springer Nature","title":"Erratum: Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation"}
